Clinical trials · New York
Lymphoma clinical trials in New York
We’re tracking 175 recruiting lymphoma studies with a site in New York — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT04989803RecruitingPhase 1/Phase 2
Tested two lymphoma cell therapies for relapsed or resistant cancer
This trial studies two investigational cell therapies (KITE-363 or KITE-753) in people whose B-cell lymphoma has returned or did not respond to prior treatment. The goal is to see how safe the treatments are and how well they can shrink the lymphoma.
New York, New YorkAges 18 years+ - NCT04972942RecruitingPhase 1
Immunotherapy for high-risk T-cell blood cancers after transplant
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Vallhala, New YorkAges Up to 39 years - NCT04996706Enrolling by invitation
Studying lymphoma prognosis and survivorship in newly diagnosed patients
This study collects health information from people recently diagnosed with lymphoma to learn more about how the disease progresses and how to improve long-term well-being. It does not test a new treatment but helps researchers better understand what affects survival and quality of life.
Rochester, New YorkAges 18 years+ - NCT04840602RecruitingPhase 2
Venetoclax plus rituximab versus standard Waldenstrom treatment
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Commack, New YorkAges 18 years+ - NCT04685616RecruitingPhase 3
Testing brentuximab with standard chemo for early Hodgkin lymphoma
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
New York, New YorkAges 16–69 - NCT04570423RecruitingPhase 2
Eflapegrastim safety study for children and teens on chemo
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
Valhalla, New YorkAges 1 month–17 years - NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Rockville Centre, New YorkAges 18 years+ - NCT03829540RecruitingPhase 1
CD4 CAR T therapy for certain CD4+ blood cancers
This early-phase (Phase 1) study tests a lab-made immune cell treatment (CD4 CAR T) for people with CD4+ leukemia or lymphoma that has come back or did not respond to standard treatment. The goal is to check safety and see how well the treatment works.
New York, New YorkAges 12 years+ - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Valhalla, New YorkAges 1–31 - NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
East White Plains, New YorkAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Lake Sucess, New YorkAges Any age - NCT00900198Recruiting
Give cancer tissue samples to help future cancer research
This study collects tissue or other cancer-related samples to help researchers better understand cancer and develop better tests or treatments. You can join if you are being evaluated for or treated for cancer, and you agree to let your samples be used for research.
Buffalo, New YorkAges 2 months+ - NCT06717347RecruitingPhase 3
Study of a new drug combo for untreated DLBCL
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
Albany, New YorkAges 18 years+ - NCT04806295Recruiting
National registry for people with blood cancers
This is a national research registry that collects information from people with blood cancer before, during, and after treatment. It may help researchers better understand care and outcomes and may connect you to future studies.
Rye Brook, New YorkAges 21 years+ - NCT07691606RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has come back
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
New York, New YorkAges 18 years+ - NCT05487170RecruitingPhase 1/Phase 2
Early trial of RNK05047 for advanced cancers
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
New York, New YorkAges 18 years+ - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Commack, New YorkAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
New York, New YorkAges 18 years+ - NCT07154823Recruiting
Blood cancer registry study for biomarker discovery
This study collects samples and health information from people with certain blood cancers to learn more about the disease and find markers that may help guide future treatments. You will not receive a treatment from this study, but you may help advance research.
Rochester, New YorkAges birth+ - NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new drug called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not gone away after treatment. The goal is to see if CTD402 can help reduce or eliminate the cancer cells in the bone marrow.
The Bronx, New YorkAges 1 year+ - NCT07052916Recruiting
Music therapy for thinking and memory after blood cancer
This study tests whether music therapy can help blood cancer survivors who have trouble with thinking, memory, or concentration. It is for people with lymphoma, leukemia, or myeloma whose disease is stable or in remission.
Commack, New YorkAges 18 years+ - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39 - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
New York, New YorkAges 18 years+
Lymphoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting lymphoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Nassau · 5 studies
- Memorial Sloan Kettering Westchester · 5 studies
- New York Medical College · 4 studies
- Memorial Sloan Kettering Commack · 3 studies
- Weill Cornell Medicine · 3 studies
- Columbia University Irving Medical Center · 2 studies
- NYU Langone Health · 2 studies
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in New York?
- Yes. We're currently tracking 175 recruiting lymphoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.